Trial Profile

Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AN 4005 (Primary)
Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Adlai Nortye

Most Recent Events

14 Aug 2026 According to an Adlai Nortye media release, clinical update from the ongoing expansion cohorts is expected to be presented at the 2026 Society for Immunotherapy of Cancer (SITC) meeting.
18 Nov 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
18 Nov 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Nov 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com